论文部分内容阅读
目的探讨布地奈特联合氨溴索雾化吸入对AECOPD的排痰效果。方法将100例AE-COPD患者随机分为观察组和对照组,各50例。观察组用生理盐水5ml+氨溴索30mg+布地奈特1mg氧驱动雾化吸入,2次/d,10～14d。对照组用生理盐水5ml+氨溴索30mg氧驱动雾化吸入,2次/d,10～14d。观察两组患者治疗前后的日排痰量、末梢静脉血氧饱和度、临床症状评分、肺功能、全身应用糖皮质激素总量、平均住院日及不良反应。结果两组比较各项观察指标均有明显改善(P<0.05),无不良反应发生。结论氨溴索联合布地奈特雾化吸入能促进排痰,改善临床症状,减少全身糖皮质激素用量,缩短住院日而且无明显不良反应。
Objective To investigate the efficacy of budesonide combined with ambroxol inhalation on expectoration of AECOPD. Methods One hundred patients with AE-COPD were randomly divided into observation group and control group, 50 cases each. Observation group with saline 5ml + ambroxol 30mg + budesonide 1mg oxygen inhalation inhalation, 2 times / d, 10 ~ 14d. Control group with saline 5ml + ambroxol 30mg oxygen inhalation inhalation, 2 times / d, 10 ~ 14d. The daily sputum volume, peripheral venous oxygen saturation, clinical symptom scores, lung function, systemic glucocorticosteroid usage, average length of stay and adverse reactions were observed before and after treatment in both groups. Results The two groups were significantly improved in all the indicators (P <0.05), no adverse reactions. Conclusion Ambroxol combined with budesonide inhalation can promote phlegm, improve clinical symptoms, reduce the amount of systemic glucocorticoid, shorten the length of stay and no obvious adverse reactions.